chronic-pain
(7)
Axonis Therapeutics
Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class oral small-molecule medicines that target KCC2, a chloride transporter that acts as the brain's master regulator of inhibitory neurotransmission. Spun out of research from Boston Children's Hospital, Harvard Medical School and Universite Laval, Axonis is advancing its lead candidate AXN-027 - a first-in-class KCC2 potentiator - toward clinical proof of concept in epilepsy, chronic pain and other CNS disorders, backed by an oversubscribed $115 million Series A closed in 2024.
Presidio Medical, Inc.
Presidio Medical is a clinical-stage medical device company in San Mateo, California, developing a proprietary Ultra Low Frequency (ULF) neuromodulation platform. By delivering very low frequency biphasic electrical currents through leads implanted in the epidural space, Presidio's spinal cord stimulation system reversibly blocks the conduction of pain signals along nerves without damaging tissue. Its first target is chronic nociceptive low back pain, a large and underserved indication with no approved SCS therapy. Backed by Deerfield Management and others, the company raised a $72M Series C in 2023 and received FDA IDE approval in 2025 to run its global pivotal FULFILL trial.
Nudge
Nudge is a San Francisco neurotechnology company building non-invasive, whole-brain interfaces powered by focused ultrasound. Founded in 2024 by Coinbase co-founder Fred Ehrsam alongside Jeremy Barenholtz and Quintin Frerichs, the company aims to stimulate and image deep brain circuits with millimeter precision - no surgery required. Its first human-ready system, Nudge Zero, is being used in research studies today, with a long-term goal of a headphone-like consumer device that lets people shift their brain state - sleep, focus, mood, habits - at the press of a button. Nudge raised a $100M Series A in July 2025 led by Thrive Capital and Greenoaks.
Michael Onuscheck
Michael Onuscheck is CEO and Chairman of Presidio Medical, a San Mateo clinical-stage neuromodulation company developing an ultra-low-frequency waveform platform aimed at chronic pain. He joined in September 2021 after two years on the board, returning to neuromodulation after leading Alcon's global businesses and, earlier, Boston Scientific's Neuromodulation division.
Swing Therapeutics, Inc.
Swing Therapeutics is a San Francisco digital therapeutics company building software-based treatments for chronic illness. Its flagship product, Stanza, is the first FDA-cleared prescription digital therapy for fibromyalgia, delivering acceptance and commitment therapy (ACT) through a smartphone in roughly 15 minutes a day. The company also operates Swing Care, a telehealth clinic that prescribes and supports the therapy across multiple states.
Hinge Health
Hinge Health is a San Francisco-based digital health company that delivers virtual care for musculoskeletal (MSK) and pelvic health conditions. It pairs an AI computer-vision motion engine (TrueMotion), an FDA-cleared wearable pain-relief device (Enso), and a remote clinical care team of physical therapists and health coaches to treat back, joint, and pelvic pain without relying on surgery or opioids. Sold mainly to employers and health plans as a benefit, it reached roughly 2,250 enterprise clients, surpassed 1.5 million lifetime members, and went public on the NYSE in May 2025 under the ticker HNGE.
Mike Rosenbluth
Mike Rosenbluth is the Founder and CEO of Swing Therapeutics, the San Francisco-based company behind Stanza - the first FDA-authorized prescription digital therapeutic for fibromyalgia symptoms. A Stanford-trained mechanical engineer with a UC Berkeley PhD in Bioengineering, Rosenbluth spent years at McKinsey, a VC firm (Versant Ventures), and cancer diagnostics company Veracyte before founding Swing in 2019. His company's landmark PROSPER-FM Phase 3 trial results were published in The Lancet in 2024, and Swing has raised over $30 million to bring evidence-based, non-drug behavioral therapy to the estimated 4 million Americans with fibromyalgia.